News

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron
Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
PMLive1h
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
Eli Lilly, Indiana Fever, YMCA, partner for new initiative to increase participation in girls basketball
The initiative, titled 'The Court Is Hers,' eliminates registration fees for girls basketball programs at the YMCA.
BioSpace8h
5 Oral Obesity Drugs Challenging Lilly’s Orforglipron
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...